Gautam Jayram, MD

In this closing segment, Dr. Charles J. Ryan leads a discussion on how clinicians integrate multiple sources of evidence when making long term treatment decisions in metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan invites the panel to discuss how clinicians evaluate evidence from observational studies and propensity matched analyses in metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan presents a clinical case scenario to explore how real world evidence informs treatment decisions in metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan and the panel explore how clinicians interpret subgroup analyses, pivotal trial data, and real world evidence when managing metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan invites the panel to discuss how clinicians interpret clinical trial results in the context of real world patient populations with metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan leads a panel discussion with Dr. Alan H. Bryce, Dr. Murilo De Almeida Luz, and Dr. Jayram on key clinical considerations that influence treatment selection when intensifying therapy for metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss how clinicians interpret data from pivotal phase 3 clinical trials evaluating androgen receptor pathway inhibitors used in combination therapy for metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan invites Dr. Jayram and Dr. Alan H. Bryce to discuss how potential central nervous system effects influence treatment selection in metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss the importance of evaluating drug drug interaction profiles when selecting androgen receptor pathway inhibitors for patients with metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce to discuss how long term tolerability influences the selection of androgen receptor pathway inhibitors for patients with metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan asks Dr. Jayram to discuss the key clinical considerations that guide the selection of androgen receptor pathway inhibitors when intensifying therapy for metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan asks Dr. Jayram to discuss the patient specific considerations that influence the transition from deciding to intensify therapy to selecting a particular treatment strategy in metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce how clinicians balance the benefits of treatment intensification with the potential for added toxicity in patients with metastatic castration sensitive prostate cancer (mCSPC), particularly in older individuals or those with significant comorbidities.

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss how treatment intensification strategies may differ across various clinical presentations of metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce to explain why androgen deprivation therapy (ADT) alone is no longer considered adequate treatment for most patients with metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan asks Dr. Jayram how the concept of survivorship has become an increasingly important consideration in the management of metastatic castration sensitive prostate cancer (mCSPC).

The discussion explores how the rising burden of comorbidities and polypharmacy in patients with metastatic castration-sensitive prostate cancer requires clinicians to carefully balance therapy intensification with overall health status, medication interactions, and long-term safety when developing individualized treatment plans.

The discussion introduces how the treatment landscape for metastatic castration-sensitive prostate cancer has evolved, highlighting that patients are now living longer with metastatic disease and often have multiple comorbidities, making long-term tolerability and quality of life key considerations in treatment planning.

"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.

Specifically, Jayram highlights pembrolizumab, nadofaragene firadenovec-vncg, and N-803 (Anktiva).

“We then talked a little bit about BCG unresponsive disease, which is a really hot topic,” says Gautam Jayram, MD.

"We...talked a little bit about BCG-unresponsive disease, which is a really hot topic; a lot of trials and a lot of data are coming there," says Gautam Jayram, MD.

Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.

Panelists discuss how to address the challenges in providing optimal care for mCRPC patients and how barriers may vary between different healthcare settings, such as rural vs. urban and private vs. public.

Panelists discuss how the dosing and administration of different abiraterone formulations vary, how food-related effects impact treatment efficacy, and strategies to manage these effects for optimal patient outcomes.

Panelists discuss how criteria such as patient comorbidities, disease progression levels, and treatment goals should be considered when selecting the appropriate form of abiraterone for patients with mCRPC, and also explore the potential benefits and drawbacks of using micronized abiraterone in specific patient populations.

Panelists discuss how the STAAR study (Stein, 2018) indicates that the micronized abiraterone formulation results in lower average serum testosterone levels in 25% of patients compared to 17% with the originator formulation, potentially influencing treatment selection.

This discussion explores the differences in the effects of abiraterone formulations when combined with prednisone or methylprednisolone.

This discussion provides an overview of abiraterone and the key differences between micronized and non-micronized formulations, including considerations for choosing between the two formulations.

Key opinion leaders discuss considerations for sequencing androgen receptor-targeted therapies in metastatic castration-resistant prostate cancer, evaluating their benefits in first-line versus second-line treatment settings.